Atlas Venture — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.
AI & Machine LearningBiotechDeep TechWaltham, US
Carole Faig(Director)Rami Daoud(Executive Officer)Diana Brainard(Director)Rick Modi(Executive Officer, Director)Luc Vandenberghe(Director)Elliott Sigal(Director)
Board seatDavid Grayzel· per SEC Form D
BiotechBoston, US
Andrew Fedder(Executive Officer, Director)Adam Friedman(Executive Officer, Director)Brian Piper(Executive Officer, Director)
Board seatJean-François Formela· per SEC Form D · $136.7M raise · filed May 2025
BiotechBoston, US
Richard Wooster(Director)Jotin Marango(Executive Officer)Jean-Francois Formela(Director)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Owen Hughes(Director)
Board seatJean-François Formela· per SEC Form D · $75M raise · filed Jul 2025
BiotechBerkeley, US
Evan Caplan(Director)Natalie Holles(Director)Charlotte McKee(Director)Thomas Gustafson(Executive Officer)Anna French(Director)Emily Conley(Executive Officer, Director)
Board seatKevin Bitterman· per SEC Form D · $30M raise · filed Jul 2025
Lexington, US
Board seatDavid Grayzel· per SEC Form D · $120.1M raise · filed Dec 2025
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.